866-897-8297

Call Is Confidential & Toll Free

Kalydeco

Kalydeco (also known as Kalydeco or VX-770) is a drug for the treatment of cystic fibrosis, developed by Vertex Pharmaceuticals and the Cystic Fibrosis Foundation. FDA approved on January 31, 2012.

Kalydeco is a cystic fibrosis transmembrane conductance regulator (CFTR). In patients with the G551D mutation, Kalydeco, a pill taken two times a day with fat-containing food, helps the protein made by the CFTR gene function better and as a result, improves lung function and other aspects of CF such as increasing weight gain.

There have been no reports of overdose with Kalydeco. The highest single dose used in a clinical study was 800 mg in a solution formulation without any treatment-related adverse events.

Imprints


Drug: Kalydeco
Strength: 150 Mg
Pill Imprint: V 150
Color: Blue
Shape: Capsule-shape

View Images & Details
Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.

Questions About Prescription Drug Addiction?

(888) 740-2069

Questions About Prescription Drug Addiction?